J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study

Johnson & Johnson's ​prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate surgery improved the chances ‌of eliminating the cancer and reduced the risk of disease progression or death, according to data from a late-stage trial presented on Sunday.